EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Subsequent Primary Hematologic Malignancies in a 21‐Year‐Old Retinoblastoma Survivor: Case Report Study

Elham Karimi, Shalaleh Abbasnezhad iD, Maedeh Arabpour iD, Sepideh Abdollahi iD, Mohammad Biglari iD, Marjan Yaghmaie iD

Cancer Reports · 2025

DOI: 10.1002/cnr2.70411 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cancer Reports, 2025. Verfasst von Elham Karimi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Retinoblastoma, Neoplasms, Second Primary, Retinal Neoplasms, Cancer Survivors. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Institute for Oncology, Hematology and Cell Therapy (RIOHCT) affiliated with Tehran University of Medical Sciences (TUMS).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Retinoblastoma (RB) is a malignant eye tumor that predominantly affects children. Although survival rates have improved significantly due to advancements in treatment, subsequent malignant neoplasms (SMNs) continue to be major causes of death in both heritable and non‐heritable RB cases. These SMNs are often associated with mutations in the RB1 gene, as well as the effects of radiotherapy or chemotherapy. There are no previous reports of a nonhereditary RB survivor developing three sequential hematologic malignancies (AML, lymphoma, and ALL) over 20 years. Most secondary primary cancers (SPCs) in RB survivors are solid tumors, such as osteosarcoma, soft tissue sarcoma, and melanoma, with hematologic malignancies being far less common, especially as third or subsequent primary tumors. Case We report a case of a 21‐year‐old Iranian male who developed multiple distinct hematologic malignancies following retinoblastoma treatment. Using NGS, Sanger sequencing, and bioinformatic analysis, the possibility of germline mutations was surveyed.

Conclusion

Germline changes associated with malignancies were examined using next‐generation sequencing (NGS). There were no germline alterations discovered, suggesting no predisposition to develop cancer. Three pathogenic/likely pathogenic heterozygous variants were found in the patient by carrier screening. Absence of germline RB1 mutations or other hereditary cancer syndromes implicates treatment‐related factors (chemotherapy/radiotherapy) as the primary driver of sequential malignancies. Nonhereditary retinoblastoma (RB) survivors have a lower risk of secondary malignancies (SMNs) compared to their hereditary counterparts. Chemotherapy, especially alkylating agents, increases the risk of secondary acute myelogenous leukemia (AML) and other leukemias and lymphomas due to its mutagenic effects and genetic factors. Although RB survivors rarely develop secondary cancers, the limited patient numbers and short follow‐up periods may influence SPC risk assessments. Continuous monitoring and personalized follow‐up care are crucial for managing long‐term risks in these survivors. This research emphasizes the essential importance of ongoing monitoring and follow‐up for survivors of retinoblastoma (RB) to identify and address secondary malignancies (SMNs), improve the management of long‐term complications, and enhance both life expectancy and quality of life.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RetinoblastomaNeoplasms, Second PrimaryRetinal NeoplasmsCancer SurvivorsHematologic NeoplasmsHumansMaleYoung AdultGerm-Line MutationRetinoblastoma Binding ProteinsHigh-Throughput Nucleotide SequencingUbiquitin-Protein Ligases

Stichwörter der Autor:innen

SMNsTRbchemotherapyretinoblastoma

Substanzen

Retinoblastoma Binding ProteinsRB1 protein, humanUbiquitin-Protein Ligases

Autor:innen und Institutionen

  • Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran.
  • Hematology, Oncology and Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran.

ORCID-Profile: Shalaleh Abbasnezhad, Maedeh Arabpour, Sepideh Abdollahi, Mohammad Biglari, Marjan Yaghmaie

Förderung

  • Research Institute for Oncology, Hematology and Cell Therapy (RIOHCT) affiliated with Tehran University of Medical Sciences (TUMS)

Zitieren

APA

Karimi, E., Abbasnezhad, S., Arabpour, M., Abdollahi, S., Biglari, M., & Yaghmaie, M. (2025). Subsequent Primary Hematologic Malignancies in a 21‐Year‐Old Retinoblastoma Survivor: Case Report Study. Cancer Reports. https://doi.org/10.1002/cnr2.70411

Vancouver

Karimi E, Abbasnezhad S, Arabpour M, Abdollahi S, Biglari M, Yaghmaie M. Subsequent Primary Hematologic Malignancies in a 21‐Year‐Old Retinoblastoma Survivor: Case Report Study. Cancer Reports. 2025. doi:10.1002/cnr2.70411

BibTeX
@article{Karimi2025,
  author = {Karimi, Elham and Abbasnezhad, Shalaleh and Arabpour, Maedeh and Abdollahi, Sepideh and Biglari, Mohammad and Yaghmaie, Marjan},
  title = {Subsequent Primary Hematologic Malignancies in a 21‐Year‐Old Retinoblastoma Survivor: Case Report Study},
  journal = {Cancer Reports},
  year = {2025},
  doi = {10.1002/cnr2.70411}
}
Kostenlos starten →